NSE: ABBOTINDIA | BSE: 500488

Falling Comet

Download real time

27780.00 55.00 (0.20%)

3,688 NSE+BSE Volume

NSE 23 Jan, 2026 3:31 PM (IST)

59,030.6

Market Cap

High in industry

Beta 1Year

Very Low volatility

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Search Inside the pdf :

Abbott India Ltd.

09 Nov 2025

27780.00

0.20%

Operational leverage at play

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) Q2FY26 revenue grew at a modest pace of 7.6% YoY. We believe moderation in growth was mainly due to discontinuation of insulin pens for Human Mixtard, Levemir and Xultophy by Novo Nordisk in India as it prioritises capacity for GLP-1 brands Ozempic and Wegovy.

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

08 Nov 2025

27780.00

0.20%

Abbott India

Buy: Abbott India Ltd.

Recommendation Target

ICICI Direct

Q2FY26- Decent print driven by growth in some power brands- Revenues grew ~8% YoY to 1757 crore. As per IQVIA, some of the power brands such as Thyronorm (Hormonal), Udiliv (GI), Cremaffin Plus (GI) and Duphalac (GI) witnessed decent growth along with some marketed brands of Novo Nordisk and Abbott Healthcare such as Rybelsus (Semaglutide) and Ryzodeg (Insulin). While Mixtard (Insulin) and Novomix (Anti-Diabetic) registered de-growth during the quarter. EBITDA grew ~14% YoY to 502...

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

17 Sep 2025

27780.00

0.20%

Steady business, outpacing Pharma peers

Buy: Abbott India Ltd.

Target

Sharekhan

Strong history of product launches: Abbott India has been steadily growing led by consistent launches of both - own and Novo Nordisk’s products (marketing). Abbott India has launched over 100 products in India in the last 12 years and we expect the pipeline to stay strong.

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

04 Jul 2025

27780.00

0.20%

Abbott India (BUY): Ascribing valuation in line with its peer GSK

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Novo's oral semaglutide Rybelsus is growing at a robust 173% CAGR over a 3Y period to Rs 4bn, as on MAT MAY'25

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

16 May 2025

27780.00

0.20%

Sustained improvement across the board

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) revenue grew 12% YoY ahead of most MNCs (avg. growth of ~10% YoY and IPM growth of ~8% YoY in Q4FY25). Abbott’s growth was aided by healthy traction in its own brands along with key brands of Novo Nordisk like Rybelsus and Ryzodeg.

Abbott has lost -20.02% in the last 6 Months

Abbott India Ltd.

29 Apr 2025

27780.00

0.20%

ERRATA: Abbott India (BUY): Mixtard discard to result in highest-ever EBITDA margin

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Novo Nordisk insulin brand outgo to result in 330 bps and 670 bps increase in EBITDA margin to 30.9% and 34.9% for FY26E and FY27E

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

11 Apr 2025

27780.00

0.20%

[Initiation] Abbott India (BUY): A safe pick amidst tariff woes

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Sales expected to reach USD 1bn, driven by industry-leading MR productivity of Rs 14.9mn by FY27E from Rs 11.5mn in FY24

Number of FII/FPI investors increased from 81 to 97 in Dec 2025 qtr.

Abbott India Ltd.

06 Feb 2025

27780.00

0.20%

Stellar quarter; growth pace accelerating

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) impressive revenue growth of 12.3% YoY in Q3FY25 was ahead of our expectation. As per IQVIA, this may be driven by key brands of Novo Nordisk like Rybelsus and Ryzodeg and owned brands like Duphalac, Udiliv and Thyronorm.